Clinical trial
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory…
NCT00179673 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00179673 |
|---|---|
| Title | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma |
| Official title | A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma |
| Lead sponsor | Celgene, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | Lenalidomide |
| Enrollment | 43 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | May 13, 2025 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: